EGFR and lung adenocarcinoma: To gain a comprehensive understanding of oncogenic driver mutations and their associated clinicopathologic characteristics of this special cohort, we concurrently investigated EGFR, ALK, ROS1 and RET alterations in samples from 280 lung adenocarcinoma patients with N1-N2 lymph node metastasis and analyzed the common and specific clinical features of different molecular alterations.